Family Vaccine Protection Act

Legislative Summary: Family Vaccine Protection Act (HR 3701)

Overview

The Family Vaccine Protection Act is a legislative proposal designed to formalize, standardize, and increase the transparency of the Advisory Committee on Immunization Practices (ACIP). The bill seeks to ensure that vaccine recommendations and the administration of vaccine programs are based strictly on a "preponderance of the best available, peer-reviewed scientific evidence."

Main Purpose and Intent

The primary goal of this bill is to codify the structure and duties of the ACIP within the Public Health Service Act. By doing so, it aims to create a rigorous, transparent, and predictable process for how the U.S. government recommends vaccines to the public, determines insurance coverage for immunizations, and manages the Vaccines for Children Program.

Key Provisions

1. Codification and Governance of the ACIP

The bill establishes a formal legal framework for the Advisory Committee, including:
* Membership: The Secretary of Health and Human Services (HHS) shall appoint 15 to 19 members based on recommendations from the Comptroller General of the United States. Members must possess specific expertise in fields such as epidemiology, immunology, and vaccine safety.
* Fixed Terms: Members serve overlapping 4-year terms, while the Chairperson serves a 7-year term.
* Ex-Officio Members: Six non-voting officials (including the Commissioners of the FDA and Directors of the NIH and Indian Health Service) are added to provide agency coordination.
* Transparency: Meetings must be open to the public, and notice of meetings must be provided in advance.

2. Evidence-Based Decision Making

The bill mandates a strict scientific standard for all recommendations:
* Scientific Standard: All guidance must be based on a "preponderance of the best available, peer-reviewed scientific evidence."
* Director's Oversight: The Director must adopt ACIP recommendations unless they determine the recommendation lacks scientific support. If a recommendation is rejected, the Director must publish the reasoning and notify Congress within 48 hours.
* Contrary Actions: If the Secretary or Director takes any action regarding vaccine use or insurance coverage that contradicts an ACIP recommendation, they must publish the scientific basis and notify Congress within 48 hours.

3. Timelines for New Vaccines

To prevent delays in public health protections, the bill requires the ACIP to:
* Consider any newly licensed vaccine at its next regularly scheduled meeting.
* Make a formal recommendation within 90 days of receiving written notification from the vaccine's license holder.

4. Vaccine Injury Compensation

The bill amends the National Vaccine Injury Compensation Program to ensure that any removal of a vaccine from the "Vaccine Injury Table" or any modification to the list of covered injuries must be supported by a preponderance of the best available scientific evidence.

Who is Affected?

• Public Health Officials: The Director of the CDC and the Secretary of HHS will face stricter reporting requirements and limited discretion when overriding scientific recommendations.
• Healthcare Providers and Insurers: The bill clarifies the process for determining which vaccines must be covered by group and individual health insurance.
• Vaccine Manufacturers: Manufacturers will have a clear timeline (90 days) for the ACIP to review newly licensed products.
• The General Public: Families gain a more transparent process for how vaccines are vetted and a more evidence-based approach to vaccine injury compensation.

Procedural and Financial Details

• Funding: The bill authorizes $2,800,000 annually from fiscal year 2026 through 2029 to cover the operating costs, compensation, and travel expenses of the Advisory Committee.
• Current Status: As of June 4, 2025, the bill has been introduced in the House and referred to the Committee on Energy and Commerce.